Family of high affinity, modified antibodies for cancer treatment
    1.
    发明授权
    Family of high affinity, modified antibodies for cancer treatment 失效
    高亲和力家族,用于癌症治疗的修饰抗体

    公开(公告)号:US06207815B1

    公开(公告)日:2001-03-27

    申请号:US08479285

    申请日:1995-06-07

    IPC分类号: C12N1514

    摘要: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VH&agr;TAG VH, CC46 VH, CC49H, CC83 VH, and CC92 VH, and CC49L, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.

    摘要翻译: 本发明涉及对人类高分子量肿瘤相关唾液酸化糖蛋白抗原(TAG-72)具有高亲和力的嵌合抗体家族。 这些抗体具有(1)介导TAG-72结合的高亲和力动物VH和VL序列,(2)人CH和CL区。 据认为,由于其人类CH和CL抗体结构域,当向人类患者施用时,它们会产生显着较少的副作用。 公开了VHαphaVV,CC46VH,CC49H,CC83VV和CC92VV,CC49L,CC83VL和CC92VV独立型序列的核苷酸和氨基酸序列,以及使用这些嵌合体的体内治疗和诊断测定方法 抗体。